Sign in
Taking people in United StatesNo phase

Contingency Management Plus Deep Transcranial Magnetic Stimulation for the Treatment of Cocaine Use Disorder

Key facts

Who runs it
The University of Texas Health Science Center, Houston
Where
Houston, United StatesSee the site
Trial code
Status
Recruiting
People taking part
100 people, planned
Started
21 Apr 2026
Expected to end
1 Sept 2029
Type of study
Interventional, 3 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • Contingency Management (CM)
  • Transcranial Magnetic Stimulation (TMS) Sham
  • Transcranial Magnetic Stimulation (TMS) experimental
Record updated
25 June 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Able to provide informed consent before any study-related activity, willing to comply with all study procedures, and be available for the duration of the study
  • Meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnostic criteria for moderate-to-severe CUD and report recent cocaine use (verified by at least one positive urine drug screen (UDS) for the cocaine metabolite benzoylecgonine (BE), during intake)
  • Agree (if the participant is female and of child-bearing potential) to use effective contraceptive methods, unless the participant's male partner(s) is surgically sterile (underwent vasectomy); Acceptable contraceptives include:
  • oral contraceptives
  • contraceptive sponge
  • patch
  • double barrier (diaphragm/spermicidal or condom/spermicidal)
  • intrauterine contraceptive system
  • etonogestrel implant
  • medroxyprogesterone acetate contraceptive injection
  • complete abstinence from sexual intercourse
  • hormonal vaginal ring; Contraceptive measures sold for emergency use after unprotected sex are not acceptable methods for routine use
  • Women of child-bearing potential must provide negative urine pregnancy test prior to randomization
  • Be able to provide the names and contact information of at least 2 persons who can consistently locate their whereabouts

Who cannot take part

  • Any contraindications to MRI scans (metal in the body; claustrophobia). -Medical implants contraindicating TMS (i.e., aneurysm clips or coils, stents, implanted stimulators, implanted vagus nerve or deep brain stimulators, implanted electrical devices such as pacemakers or medication pumps, electrodes for monitoring brain activity, cochlear implants for hearing, any magnetic implants, bullet fragments, any other metal device or object implanted in your body closer than 30 cm from the coil)
  • Current DSM-5 diagnosis for substance use disorder (of at least moderate severity) other than cocaine, cannabis, or nicotine or a substance Use Disorder (SUD) requiring medical detoxification (e.g., alcohol, opioid, benzodiazepine)
  • Presence of any medical, neurological, psychiatric, or physical condition, disease, or illness (including psychosis and bipolar disorder) that, in the opinion of the PIs and the Certified Registered Nurse Anesthetist (CNRA)Medical Director could: (a) compromise interfere, limit, or reduce the subject's ability to complete the study; or (b) adversely impact the safety of the subject or the integrity of the data
  • History of brain surgery
  • History of an intracranial lesion or any medical or neurological diagnosis/condition associated with increased intracranial pressure (i.e., Idiopathic Intracranial Hypertension/Pseudotumor Cerebri) OR any of the following symptoms within 30 days of enrollment: headaches > 15 days/month, loss of vision or decreased vision
  • Moderate-to-severe heart disease
  • History of stroke
  • Taking any antidepressant or antipsychotic medication at a dose above the maximum recommended dose or at a dose deemed to be potentially unsafe according to the study physician; has taken any of the following medications, which are known to increase the risk of seizures, within 1 week of study enrollment; or does not agree to abstain from taking the following medications during study participation:; clozapine; chlorpromazine; bupropion; clomipramine hydrochloride; amoxapine; maprotiline hydrochloride; diphenhydramine; stimulants other than cocaine including the following:; Dextroamphetamine and amphetamine ii. Dextroamphetamine iii. Lisdexamfetamine dimesylate iv. Methamphetamine; Methylphenidate i. tramadol j. isoniazid
  • Personal history of epilepsy or seizure disorder and/or family history including a first degree relative
  • Having conditions of probation or parole requiring reports of drug use to officers of the court or impending incarceration
  • For adolescent aged participants (18-21 only): any risk factor for neurocardiogenic syncope (history of syncope/ presyncope related to noxious stimuli, anxiety, micturition, or posture)
  • Has current or recent (within 3 months of potential enrollment) suicidal ideation, suicidal behavior, homicidal ideation or a homicidal plan sufficient to raise subject safety concerns based on the following assessments:; Structured Clinical Interview for DSM-5 (SCID-5); Columbia-Suicide Severity Rating Scale - Answers YES to Questions 3, 4, 5, or 6; Assault \& Homicidal Danger Assessment Tool - Key to Danger > 1
  • Serious head injury with loss of consciousness
  • Pregnant or nursing for female participants
  • Inability to read, write, or speak English

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • The University of Texas Health Science Center at HoustonHouston, United StatesContact: Joy M Schmitz, PhDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the effects of Contingency Management (CM)+transcranial magnetic stimulation (TMS) on treatment outcomes in individuals who are initial non-responders and to evaluate the effects of CM+TMS on putative mechanisms of change

The 3 groups in the trial

  • CM for 2 weeks then CM onlyTreatment being tested

    Treatment: Contingency Management (CM)

  • CM for 2 weeks, then TMS sham plus CMSham treatment, for comparison

    Treatment: Contingency Management (CM) and Transcranial Magnetic Stimulation (TMS) Sham

  • CM for 2 weeks, then TMS experimental plus CMTreatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Contingency Management Plus Deep Transcranial Magnetic Stimulation for the Treatment
Fit questions
Built from NCT07490600, who can take part
Publications
Record updated
25 June 2026
Contingency Management Plus Deep Transcranial Magnetic Stimulation for the Treatment of Cocaine Use Disorder (NCT07490600) – Frontlight Research